← Eichor
Study identifier: NCT06875089 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

A Pilot Study to Assess the Feasibility and Acceptability of Newborn Screening Using in Silico Panel-based Solo Genome Sequencing in France

Condition: Newborn Screening Programmes for Rare Diseases  ·  Sponsor: Centre Hospitalier Universitaire Dijon

PhaseN/A
Planned participants5000
Who can joinAll sexes, 0 Days to 28 Days
Healthy volunteersNo

About this study

Newborn Screening (NBS) based on genome sequencing (GS) is currently the subject of particular attention at both European and international levels. Over the past three years, several publications have discussed the opportunities and challenges of using GS for NBS. To date, only two Chinese programs have published their results, the first on a series of 29,601 healthy newborns and the second on a series of 10,334 healthy newborns and 668 high-risk infants. Globally, more than twenty pilot projects are underway, although none has been initiated within the French context thus far. Across the different pilot projects, various study designs are used. Most have opted for a targeted GS-based analysis to screen for pediatric-onset diseases. Some projects focus solely on diseases for which effective drugs or interventions exist to prevent or reduce symptoms. In contrast, others offer parents the option to screen their newborns for diseases without current treatment options, but for which a treatment is underdevelopment, or with interest in early management, a choice exercised by most parents. Indeed, early diagnosis of these diseases can help to introduce treatments or interventions when they become available, to participate in research trials on new treatments and to receive early management and genetic counseling. In France, the national NBS program has long been recognized worldwide for its organizational quality and comprehensiveness, although, until recently, it has one of the l…

This description comes directly from the study's public registry record.

Talk to the study team

Laurence OLIVIER-FAIVRE  ·  0380295313  ·  laurence.faivre@chu-dijon.fr

Always discuss trial participation with your own doctor first.

Locations (5)

CHU d'AngersAngers, FranceNot Yet Recruiting
CHU BesançonBesançon, FranceNot Yet Recruiting
CHU Dijon BourgogneDijon, FranceRecruiting
CHU Hôtel DieuNantes, FranceNot Yet Recruiting
CHU Rennes - Hôpital SudRennes, FranceNot Yet Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06875089